News
30 Sep 2020
BioVectra Inc. excited for continued growth under experienced CDMO investor, H.I.G. Capital
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million— Transaction continues to advance Mallinckrodt’s strategic focus on branded biopharmaceuticals by monetizing a non-core business —— H.I.G. Capital to support BioVectra leadership and its attractive growth plan —
Mentioned Companies
BioVectra Inc.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance